QTREX Quantum (QTEX) awards CTO 550,000 RSUs with staged vesting

Rhea-AI Filing Summary

Yechezkely Hayon Daniella reported acquisition or exercise transactions in this Form 4 filing.

QTREX Quantum Ltd. granted its Chief Technology Officer, Daniella Yechezkely Hayon, an award of 550,000 restricted share units representing ordinary shares on July 6, 2026 at $0.00 per share. Following this grant, she reports ownership of 1,330,000 ordinary shares, held directly. The RSUs were granted under the company’s 2019 Plan, with 183,334 units vesting on July 1, 2027 and the remaining units vesting on a quarterly basis over two years after that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yechezkely Hayon Daniella

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	550,000	$0.00	--

Holdings After Transaction: Ordinary Shares — 1,330,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 550,000 units Grant price: $0.00 per share Shares owned after award: 1,330,000 ordinary shares +1 more

4 metrics

RSUs granted 550,000 units Award of restricted share units on July 6, 2026 to the CTO

Grant price $0.00 per share Reported price per ordinary share for this RSU award

Shares owned after award 1,330,000 ordinary shares Directly held following the July 6, 2026 transaction

First vesting tranche 183,334 RSUs Restricted share units scheduled to vest on July 1, 2027

Key Terms

Restricted Share Units, 2019 Plan, vesting on a quarterly basis

3 terms

Restricted Share Units financial

"The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s 2019 Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Plan financial

"were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan"

vesting on a quarterly basis financial

"the remaining RSUs will vest on a quarterly basis over two years"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/14/2026 - 05:43 PM Accepted by SEC EDGAR 07/14/2026 - 05:43 PM Learn about SEC filing dates

FAQ

What insider transaction did QTREX Quantum (QTEX) report for its CTO?

QTREX Quantum’s Chief Technology Officer, Daniella Yechezkely Hayon, received a grant of 550,000 restricted share units at $0.00 per share. The award represents compensation under the company’s 2019 Plan rather than an open-market share purchase.

How many QTREX Quantum (QTEX) shares does the CTO hold after the grant?

After the July 6, 2026 award, the CTO reports holding 1,330,000 ordinary shares directly. This figure reflects her beneficial ownership position as reported, including the impact of the newly granted restricted share units.

What is the vesting schedule for the 550,000 RSUs at QTREX Quantum (QTEX)?

The RSU grant vests in stages: 183,334 units vest on July 1, 2027, and the remaining units vest on a quarterly basis over the following two years. Vesting is tied to QTREX Quantum’s 2019 Plan conditions.

Was the QTREX Quantum (QTEX) CTO’s award an open-market share purchase?

No. The CTO’s acquisition of 550,000 units was a grant/award at $0.00 per share under QTREX Quantum’s 2019 Plan. It represents equity compensation, not a discretionary open-market stock purchase.

Under which plan were the CTO’s RSUs granted at QTREX Quantum (QTEX)?

The restricted share units were granted under Qtrex Quantum Ltd.’s 2019 Plan, originally adopted when the company was known as Insense Medical. The plan governs the vesting schedule and other terms of the RSU award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yechezkely Hayon Daniella

(Last) (First) (Middle)

2 HA-TIDHAR ST.

(Street)

RA'ANANA 4366504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
QTREX Quantum Ltd. [ QTEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/06/2026		A		550,000(1)	A	$0	1,330,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

	/s/ Daniella Yechezkely Hayon	07/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)